Shinji Ohie Selected Research

TAC 101

3/2008	A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma.
1/2005	4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induces apoptosis in colon cancer partially through the induction of Fas expression.
1/2004	4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid inhibits angiogenesis in colon cancer through reduced expression of vascular endothelial growth factor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shinji Ohie Research Topics

Disease

3	Neoplasms (Cancer) 03/2008 - 01/2004
2	Neoplasm Metastasis (Metastasis) 01/2005 - 01/2004
2	Colonic Neoplasms (Colon Cancer) 01/2005 - 01/2004
1	Carcinoma (Carcinomatosis) 03/2008
1	Ovarian Neoplasms (Ovarian Cancer) 03/2008
1	Clear Cell Adenocarcinoma 03/2008
1	Weight Loss (Weight Reduction) 01/2005

Drug/Important Bio-Agent (IBA)

3	TAC 101IBA 03/2008 - 01/2004
3	Benzoic Acid (Potassium Benzoate)FDA Link 03/2008 - 01/2004
1	Pharmaceutical PreparationsIBA 03/2008
1	RetinoidsIBA 03/2008
1	Cisplatin (Platino)FDA LinkGeneric 03/2008
1	Fas Ligand Protein (Fas Ligand)IBA 01/2005
1	Single-Stranded DNA (DNA, Single Stranded)IBA 01/2005
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2004

Therapy/Procedure

1	Therapeutics 03/2008
1	Laparotomy 01/2005
1	Oral Administration 01/2005